KDR and hepatocellular carcinoma: For example, in a phase Ib/II HCC trial, patients with high MET mRNA expression showed a threefold increase in progression-free survival compared to patients with low c-MET expression when given a combination of the anti-VEGFR-2 mAb ramucirumab plus the anti-MET mAb emibetuzumab [34].